RESUMEN
This study aimed to evaluate the efficacy of an emodepside 2.1 % (w/v)/praziquantel 8.6 % (w/v) topical solution (Profender® spot-on for cats) in the prevention of lactogenic Toxocara cati infections. A controlled test was performed with two groups of 8 cats with confirmed pregnancy. All cats were infected with daily doses of 2000 T. cati eggs for 10 consecutive days starting 50 days post conception to produce an acute infection. Treatment was performed 60 days post conception. Queens in the treatment group received the emodepside/praziquantel solution at the minimum therapeutic dose (3 mg/kg emodepside and 12 mg/kg praziquantel), while the control group was treated with a placebo spot-on. Efficacy was evaluated 56 days post partum by necropsy of one randomly selected kitten of each litter and comparison of the worm burdens between the study groups. Additionally the necropsy results were supported by quantification of worms expelled with the faeces after deworming of the remaining kittens and all queens. The treatment in late pregnancy resulted in an efficacy of 98.7 % (p < 0.0001). All necropsied control kittens were infected (geometric mean 30.6). Seven of 8 kittens from treated mothers were free of T. cati (geometric mean 0.4). Worm counts after deworming reflected the results obtained at necropsy. No side effects of the treatment were observed. It is concluded that treatment with an emodepside/praziquantel spot-on solution during late pregnancy effectively prevents lactogenic transmission of T. cati to the offspring. The study design facilitated the generation of reliable data, while at the same time a minimum number of animals was sacrificed.
Asunto(s)
Antihelmínticos/uso terapéutico , Enfermedades de los Gatos/tratamiento farmacológico , Depsipéptidos/uso terapéutico , Transmisión Vertical de Enfermedad Infecciosa/veterinaria , Praziquantel/uso terapéutico , Administración Tópica , Animales , Antihelmínticos/administración & dosificación , Enfermedades de los Gatos/parasitología , Gatos , Depsipéptidos/administración & dosificación , Combinación de Medicamentos , Heces/parasitología , Femenino , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Praziquantel/administración & dosificación , Embarazo , Toxocara/efectos de los fármacos , Toxocariasis/tratamiento farmacológicoRESUMEN
This study aimed to evaluate the efficacy of imidacloprid 10 %/moxidectin 2.5 % (w/v) spot-on (Advocate®/Advantage® Multi, Bayer) against adult Dirofilaria repens in a blinded, placebo-controlled randomised laboratory study. Twenty-four Beagle dogs were experimentally infected with approximately 75 infective D. repens larvae each on study day (SD) 0. Treatment was initiated on SD 228 after patency had been confirmed in 21 dogs, using a modified Knott Test. Eleven dogs received monthly treatments with imidacloprid/moxidectin at the minimum therapeutic dose (10 mg/kg imidacloprid and 2.5 mg/kg moxidectin) for six consecutive months and 12 control dogs were treated with a placebo formulation. Approximately one month after the last treatment, all dogs were euthanised and necropsied for the detection of D. repens worms. Eleven control dogs harboured live adult D. repens (range 2-11, geometric mean 5.44). Eight of 11 imidacloprid/moxidectin-treated dogs were free of live worms. The live worm count was reduced by 96.2 % (range 0-1, geometric mean 0.21). The majority of dead worms were encapsulated and degenerated. After the first treatment, Knott Tests were negative in all imidacloprid/moxidectin-treated dogs and this status was maintained in 10 dogs until study end. One dog showed a low microfilariae count (1 and 4/mL) on four occasions but was also negative before necropsy. The treatment was well tolerated by all study animals. It is concluded that six consecutive monthly treatments with imidacloprid/moxidectin spot-on are effective and safe against adult D. repens and provide an option for preventing the further spread of this zoonotic parasite.
Asunto(s)
Dirofilaria repens/efectos de los fármacos , Dirofilariasis/tratamiento farmacológico , Enfermedades de los Perros/tratamiento farmacológico , Imidazoles/uso terapéutico , Macrólidos/uso terapéutico , Nitrocompuestos/uso terapéutico , Animales , Dirofilariasis/parasitología , Enfermedades de los Perros/parasitología , Perros , Método Doble Ciego , Imidazoles/administración & dosificación , Larva , Macrólidos/administración & dosificación , Microfilarias , Neonicotinoides , Nitrocompuestos/administración & dosificaciónRESUMEN
Notoedric mange (feline scabies) is a rare, but highly contagious disease of cats and kittens caused by Notoedres cati (N. cati), which can infest other animals and also humans. The study objective was to determine the efficacy and safety of 10 % imidacloprid/ 1 % moxidectin (Advocate®/Advantage® Multi spot-on for cats) against natural N. cati infestation in cats. Sixteen cats were randomly assigned to treatment group or negative control using pre-treatment mite counts. The treatment group received a single spot on treatment of the investigational veterinary product (IVP) according to label instructions. The control group stayed untreated. Five cats from the negative control were treated with the IVP at the end of the study and observed for 28 days to increase the treatment group. Skin scrapings and mite counts were performed 28 days post treatment (p.t.). Notoedric skin lesion assessments with clinical scoring were performed regularly. Five animals had to be removed prematurely from the study population due to different reasons. The number of viable N. cati mites in all treated animals 28 days p.t. was zero compared with 2.8 ± 3.0 in the negative control, being significantly lower for treated cats (p = 0.0019, Wilcoxon test). The resulting efficacy was 100 %. Clinical cure based on skin lesion assessment was achieved 28 days p.t. in 100 % of all treated animals completing 28 study days. The IVP was well tolerated and applied at the minimal therapeutic dose (10 mg imidacloprid/1 mg moxidectin/kg body weight) a high therapeutic efficacy in curing N. cati infestations and feline scabies clinical symptoms was recorded.
Asunto(s)
Acaricidas/uso terapéutico , Enfermedades de los Gatos/tratamiento farmacológico , Imidazoles/uso terapéutico , Macrólidos/uso terapéutico , Infestaciones por Ácaros/veterinaria , Nitrocompuestos/uso terapéutico , Sarcoptidae/efectos de los fármacos , Acaricidas/efectos adversos , Administración Tópica , Animales , Gatos , Combinación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Imidazoles/efectos adversos , Macrólidos/efectos adversos , Infestaciones por Ácaros/tratamiento farmacológico , Infestaciones por Ácaros/parasitología , Neonicotinoides , Nitrocompuestos/efectos adversos , Carga de Parásitos , Piel/parasitología , Piel/patología , Resultado del TratamientoRESUMEN
The efficacy of emodepside plus toltrazuril oral suspension for dogs (Procox®, Bayer) against Trichuris vulpis was evaluated in a controlled, blinded and randomised laboratory study. Twenty naturally infected dogs were included. Dogs in the treatment group received the minimum therapeutic dose of 0.45 mg emodepside and 9 mg toltrazuril per kg body weight, while dogs in the control group were left untreated. Efficacy was calculated based on worm counts after necropsy on Day 7 post treatment. Additionally, all faeces were collected and examined for expelled worms. The treatment was 100 % effective. A total of 233 adult worms (geometric mean 17.0) and 3 immature adult worms were found in the control group at necropsy. Adequacy of infection was demonstrated. The treated group excreted a total of 186 adult worms within 2 days after treatment. Additionally, all dogs were co-infected with Uncinaria stenocephala. Efficacy against this parasite was 99.8 %. No side effects of the treatment were observed. This study demonstrates that in addition to the formerly proven efficacy against Toxocara canis, Ancylostoma caninum and Uncinaria stenocephala, emodepside plus toltrazuril suspension is also effective against T. vulpis and thus represents a convenient treatment option for dogs co-infected with whipworms and coccidia.
Asunto(s)
Antihelmínticos/administración & dosificación , Depsipéptidos/administración & dosificación , Suspensiones/administración & dosificación , Triazinas/administración & dosificación , Tricuriasis/veterinaria , Administración Oral , Ancylostomatoidea/aislamiento & purificación , Animales , Antihelmínticos/efectos adversos , Coinfección/tratamiento farmacológico , Coinfección/parasitología , Coinfección/veterinaria , Depsipéptidos/efectos adversos , Perros , Método Doble Ciego , Combinación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Heces/parasitología , Carga de Parásitos , Resultado del Tratamiento , Triazinas/efectos adversos , Tricuriasis/tratamiento farmacológico , Tricuriasis/parasitología , Trichuris/aislamiento & purificaciónRESUMEN
The efficacy of imidacloprid 10 %/moxidectin 2.5 % (Advocate®, Advantage® Multi, Bayer) against experimental Dirofilaria (D.) repens infection in dogs was evaluated in a blinded, negative controlled randomised laboratory efficacy study. On SD (study day) 0, eight dogs received a spot-on treatment at a dose of 10 mg imidacloprid and 2.5 mg moxidectin per kg body weight. Another 8 dogs were left untreated. On SD 28 each dog was infected with approximately 75 infective D. repens larvae. Blood samples were collected every 4 weeks after treatment. A modified Knott test was conducted to detect mf (microfilaria). PCR analysis was performed with mf-positive blood samples. On SDs 245 and 246, all dogs were euthanised for detection of D. repens worms. Blood samples of all treated dogs were negative for mf at all sampling days. Blood samples of control dogs were positive for mf in 5 out of 8 control dogs. Individual mf counts ranged from 7 to 2800 mf/ml. In mf-positive blood samples, only D. repens was identified by PCR analysis. During necropsy D. repens worms could be detected in eight untreated control dogs (range: 321 worms per dog), whereas no worm could be detected in any of the treated dogs. These results indicate a 100 % preventive efficiency of a single spot-on treatment of imidacloprid 10 %/moxidectin 2.5 % in dogs against experimental infection with D. repens (L3 larvae). The product was well tolerated in all study animals, no treatment related adverse reactions were observed throughout the study.
Asunto(s)
Antihelmínticos/administración & dosificación , Dirofilaria repens/aislamiento & purificación , Dirofilariasis/prevención & control , Enfermedades de los Perros/prevención & control , Imidazoles/administración & dosificación , Macrólidos/administración & dosificación , Nitrocompuestos/administración & dosificación , Animales , Sangre/parasitología , Dirofilaria repens/genética , Dirofilariasis/parasitología , Enfermedades de los Perros/parasitología , Perros , Método Doble Ciego , Combinación de Medicamentos , Neonicotinoides , Carga de Parásitos , Placebos/administración & dosificación , Reacción en Cadena de la Polimerasa , Resultado del TratamientoRESUMEN
The miticide efficacy of a single treatment with Felpreva® (tigolaner, emodepside and praziquantel) spot-on solution for cats was evaluated in two European field studies. One study was conducted in cats naturally infested with Otodectes cynotis. The other study was conducted in cats naturally infested with Notoedres cati. In both studies, the presence of viable mites was confirmed prior to treatment (Day -1/Day 0) and re-evaluated on Day 14 (O. cynotis study) and on Day 28 (both studies). Efficacy was calculated based on the number of viable mites found after treatment. In the O. cynotis study, the primary criterion was the percentage of mite-free cats after treatment with Felpreva® compared to a sarolaner/selamectin combination (Stronghold® Plus, Zoetis) as a positive control. In the N. cati study, the primary criterion was the difference between arithmetic mean mite counts of cats treated with Felpreva® and cats treated with a placebo formulation (solketal). Secondary criteria in both studies were changes in clinical lesion scores after treatment. In both studies, all Felpreva®-treated cats were mite-free (100% parasitological cure) on Day 28, 4 weeks after treatment. Signs of mange on Day 28 were clinically improved in all O. cynotis-infested cats (100%) and clinically cured in all N. cati-infested cats (100%). There were no records of any adverse events or application site reactions in Felpreva®-treated cats.
RESUMEN
Five studies (two dose determination, two dose confirmation, and one speed of flea kill study) were conducted to assess the immediate (therapeutic) efficacy and long-term persistent (preventive) efficacy of a single spot-on application containing the novel acaricide and insecticide tigolaner in combination with emodepside and praziquantel (Felpreva®, Vetoquinol S.A. Lure, France) applied to cats artificially infested with Ctenocephalides felis. Eight cats per group were randomly allocated to 0, 1×, 1.3× and 2× of the minimum dose (14.5 âmg/kg body weight) of tigolaner (dose determination studies) or randomly allocated to 0 and 1× of the dosage (dose confirmation studies). Onset of efficacy was assessed in a speed of flea kill study on an existing flea infestation 8, 12 and 24 âh after treatment and reassessed after monthly flea reinfestation until 13 weeks post-treatment. Efficacy was calculated according to the Abbott formula using arithmetic means. Efficacy was claimed when (i) control groups were adequately infested (flea retention ≥ 50%) at each time-point in the studies; (ii) flea counts in treated groups were significantly lower (P â≤ â0.05) than flea counts in control groups; and (iii) calculated efficacy was ≥ 90% (speed of flea kill study) and ≥ 95% (dose determination and dose confirmation studies). Tigolaner at 14.5 âmg/kg body weight was 100% effective against fleas on Day 1 (immediate, therapeutic efficacy) in both, dose determination and dose confirmation studies. The long-term persistent efficacy in week 13 ranged between 96.3% and 100%. Fleas were rapidly killed within 12 âh after treatment (100% flea reduction, immediate efficacy). New flea infestations were successfully prevented for 8 weeks (98.9-100% flea reduction) within 8 âh after reinfestation, and at week 13 (96.3% flea reduction) within 24 âh after reinfestation.
RESUMEN
The efficacy of Felpreva® (Vetoquinol), a new spot-on application containing the novel acaricide and insecticide tigolaner in combination with emodepside and praziquantel, was evaluated in cats artificially infested with ear mites (Otodectes cynotis). A total of three pivotal dose confirmation studies were conducted, two of them designed as non-interference studies. Cats were artificially infested with O. cynotis mites and randomly allocated into groups of 8 cats based on pre-treatment mite counts. Cats were treated once on Day 0, either with Felpreva® (14.5 âmg/kg tigolaner, 3 âmg/kg emodepside and 12 âmg/kg praziquantel) or with placebo. Studies with a non-interference design included two additional groups of cats, treated with Profender® spot-on solution (Vetoquinol) (3 âmg/kg emodepside and 12 âmg/kg praziquantel) and tigolaner as a mono product (14.5 âmg/kg tigolaner). Efficacy was evaluated on Day 28/Day 30 based on total live mite counts after ear flushing. Efficacy was claimed when: (i) at least six control cats per group were adequately infested with mites; (ii) calculated efficacy was ≥ 90% based on geometric mean mite counts; and (iii) the difference in mite counts between Felpreva®-treated cats and control cats was statistically significant (P â≤ â0.05). In two of the three studies, Felpreva®-treated cats were mite-free (100% efficacy) on Day 28/Day 30 and almost full efficacy (99.6%) was seen in the third study. The difference in mite counts between Felpreva®-treated cats and control cats was significant (P â< â0.0001) in all three studies. All control cats were adequately infested in all three studies. The efficacy of Felpreva® against ear mite (Otodectes cynotis) infection in cats was confirmed.
Asunto(s)
Angiostrongylus/efectos de los fármacos , Antinematodos/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Macrólidos/uso terapéutico , Neonicotinoides/uso terapéutico , Nitrocompuestos/uso terapéutico , Infecciones por Strongylida/tratamiento farmacológico , Infecciones por Strongylida/veterinaria , Animales , Perros , Combinación de Medicamentos , Femenino , Tracto Gastrointestinal/parasitología , Imidazoles/uso terapéuticoAsunto(s)
Antinematodos/uso terapéutico , Capillaria/efectos de los fármacos , Enfermedades de los Perros/tratamiento farmacológico , Infecciones por Enoplida/tratamiento farmacológico , Infecciones por Enoplida/veterinaria , Macrólidos/uso terapéutico , Neonicotinoides/uso terapéutico , Nitrocompuestos/uso terapéutico , Administración Tópica , Animales , Perros , Combinación de Medicamentos , Femenino , Imidazoles/uso terapéutico , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/parasitología , Infecciones del Sistema Respiratorio/veterinaria , Resultado del TratamientoRESUMEN
The present field study evaluated the safety and 3-month preventive efficacy of a novel spot-on endectocide containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infested by fleas (Ctenocephalides felis) and/or ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus spp.). The efficacy of Felpreva® to reduce the clinical signs associated with flea allergy dermatitis was also evaluated. A total of 326 cats, i.e. 120 and 206 infested by ticks and fleas respectively, from 16 different sites located in Hungary and Portugal were included on Day 0 and allocated in two Groups at a ratio of 2:1 (T1:T2). Cats of T1 were treated with Felpreva®, while cats of T2 were dosed with a commercial Control Product (Bravecto®, MSD Animal Health) licensed for the same indications. Of the 120 tick-infested cats, 79 and 41 were treated with Felpreva® and Bravecto® respectively, while of the 206 flea-infested cats, 139 were treated with Felpreva® and 67 with Bravecto®. Cats were physically examined on Days 7, 28, 56, 75 and 90; when present, fleas and ticks were counted and collected. Efficacy evaluation was based on the mean percent reduction of live parasite counts for each of five visits versus the pre-treatment count. Percent reductions of live flea and tick counts over all post-baseline periods were 99.74% (T1) versus 98.56% (T2) and 97.50% (T1) versus 98.65% (T2), respectively. Non-inferiority for the Felpreva® compared with the Bravecto® treated group was statistically demonstrated for both fleas and ticks. Three adverse events were observed and considered unlikely related to the treatment. These results show that the new topical combination product Felpreva® is safe and highly efficacious in treating flea and tick infections in cats for at least three months (90 days) with a single administration. In 16 cats that were identified with flea allergy dermatitis, the clinical signs of flea allergy dermatitis improved following treatment in both groups.
RESUMEN
This paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infected with major intestinal nematodes (Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala) and/or cestodes (Dipylidium caninum, Taenia taeniaeformis) and/or lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior). A total of 219 cats from 26 veterinary clinics located in Albania, Greece, Hungary, Italy and Portugal were included in the study. Feces from the cats were examined on a single occasion between Study Day -7 and Day 0 (baseline) and post-treatment (i) twice between Day 7 and Day 14 (± 2) (for intestinal helminths) or (ii) twice between Day 21 (± 2) and Day 28 (± 2) (for lungworms). Cats were allocated into two groups at a ratio of 2:1 (Felpreva®: Profender®, i.e. a commercial control product containing emodepside and praziquantel). Cats infected with intestinal helminths were treated once on Day 0 (i) with Felpreva® (Group 1) or (ii) with Profender® (Group 2). Animals infected with lungworms received a second treatment with Profender® on Day 14 (± 2) regardless of group allocation. Faecal egg or larval count reduction for Felpreva® was 97.47% for intestinal nematodes and 96.80% for lungworms. No cats infected with cestodes at baseline resulted positive after treatment with Felpreva®. However, the low number of cats (n = 10) did not allow for a statistical analysis to be performed. Non-inferiority of Felpreva® compared to Profender® was statistically demonstrated for all target intestinal and respiratory parasites. No adverse events nor application site reactions were observed. These results show that the new topical combination product Felpreva® is highly safe and efficacious in treating infections caused by major species of feline intestinal nematodes, cestodes and lungworms under field conditions.
RESUMEN
The coccidia Isospora felis and Isospora rivolta are intestinal parasites occurring worldwide in domestic cats. In young cats, they can be detected with higher prevalence.The effects of toltrazuril in the new combination product Procox(®) oral suspension for dogs containing 0.1 % emodepside and 2 % toltrazuril (0.9 mg emodepside + 18 mg toltrazuril per ml) were studied in eighteen kittens experimentally infected each with a total of 1 x 10(5) oocysts of a mixture of Isospora felis and Isospora rivolta. In the infectious material, the quantitative relation of I. felis and I. rivolta was about 1:5. Following a three-days period after infection, two groups of 6 kittens were treated during the prepatent period with either a single dose of 0.45 mg emodepside + 9 mg toltrazuril/kg body weight or 0.9 mg emodepside + 18 mg toltrazuril/kg body weight. A group of six kittens without any treatment served as a control. On day 5 post infection, the untreated kittens started the excretion of oocysts. Treatment with both toltrazuril doses significantly reduced oocyst excretion. Following the single higher dose, the reduction of oocysts of both Isospora spp. was more pronounced (96.7 % to 100 %) in comparison to the lower dose (57.2 % to 100 %). The Procox(®) application was well tolerated and no adverse events were seen with any of the applied dosages.When administered to kittens and as a single treatment during the prepatent period, Procox(®) is suitable to control the number of oocysts excreted in the faeces in case of an Isospora felis and Isospora rivolta infection.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Coccidiostáticos/uso terapéutico , Depsipéptidos/uso terapéutico , Parasitosis Intestinales/veterinaria , Isospora/efectos de los fármacos , Isosporiasis/veterinaria , Triazinas/uso terapéutico , Administración Oral , Animales , Enfermedades de los Gatos/parasitología , Gatos , Coccidiostáticos/administración & dosificación , Depsipéptidos/administración & dosificación , Diarrea/tratamiento farmacológico , Combinación de Medicamentos , Evaluación de Medicamentos , Parasitosis Intestinales/tratamiento farmacológico , Isosporiasis/tratamiento farmacológico , Isosporiasis/parasitología , Triazinas/administración & dosificaciónRESUMEN
Two exploratory studies were performed to determine the optimum therapeutic dose of Procox(®) for the removal of experimental infection with mature adult Toxocara (T.) cati and Ancylostoma (A.) tubaeforme in kittens. Procox(®) is a new oral suspension containing a combination of the nematocidal and coccidiocidal active principles emodepside (0.1 %) and toltrazuril (2 %).In the first study, 18 eight-weeks-old kittens were inoculated with 450 L3 larvae of T. cati. 56 days after infection, the kittens were allocated to three treatment groups and were treated with 0.5 mg emodepside/kg body weight (group 1), 0.25 mg emodepside/kg body weight (group 2) and 0.1 mg emodepside/kg body weight (group 3), respectively. In the second study, 10 eight-weeks-old kittens were inoculated with 350 L3 larvae of A. tubaeforme. Four weeks after infection, the kittens were allocated to two treatment groups and were treated with 0.1 mg emodepside/kg body weight (group 1) or 0.25 mg emodepside/kg body weight (group 2). In both studies, all kittens received a reference treatment with Drontal(®) (230 mg pyrantel embonate and 20 mg praziquantel per tablet) at the recommended dose of one tablet/4 kg body weight 5 days after treatment with Procox(®). Anthelmintic efficacy was calculated by reduction in worm numbers expelled with the faeces following treatment with Procox(®) as compared with faecal worm numbers after reference treatment with Drontal(®), by thus avoiding necropsy of the animals.In the T. cati study, emodepside was at 99.9 %, 100 % and 96.5 % effective at a dosage of 0.5 mg, 0.25 mg and 0.1 mg per kg body weight, respectively. Against A. tubaeforme emodepside was at 95.7 % and 100 % effective at a dosage of 0.1 mg and 0.25 mg per kg body weight. No adverse events were seen during either study.It can be concluded that Procox(®) is efficacious for the control of mature adult T. cati and A. tubaeforme infections in cats at a single-dose rate of 0.25 mg emodepside/kg body weight.
Asunto(s)
Ancylostoma/efectos de los fármacos , Anquilostomiasis/veterinaria , Enfermedades de los Gatos/tratamiento farmacológico , Depsipéptidos/uso terapéutico , Toxocara/efectos de los fármacos , Toxocariasis/tratamiento farmacológico , Triazinas/uso terapéutico , Administración Oral , Anquilostomiasis/tratamiento farmacológico , Anquilostomiasis/parasitología , Animales , Antinematodos/administración & dosificación , Antinematodos/uso terapéutico , Enfermedades de los Gatos/parasitología , Gatos , Depsipéptidos/administración & dosificación , Combinación de Medicamentos , Evaluación de Medicamentos , Larva/efectos de los fármacos , Larva/patogenicidad , Recuento de Huevos de Parásitos/veterinaria , Toxocariasis/parasitología , Triazinas/administración & dosificaciónRESUMEN
BACKGROUND: In three randomized, controlled laboratory efficacy studies, the efficacy in the prevention of patent infections of a topical combination of imidacloprid 10%/moxidectin 1% (Advocate® spot-on formulation for cats, Bayer Animal Health GmbH) against larval stages and immature adults of Aelurostrongylus abstrusus, as well as the treatment efficacy of a single or three monthly treatments against adult A. abstrusus, were evaluated. METHODS: Cats were experimentally inoculated with 300-800 third-stage larvae (L3). Each group comprised 8 animals and the treatment dose was 10 mg/kg bodyweight (bw) imidacloprid and 1 mg/kg bw moxidectin in each study. Prevention of the establishment of patent infections was evaluated by two treatments at a monthly interval at three different time points before and after challenge infection. Curative efficacy was tested by one or three treatments after the onset of patency. Worm counts at necropsy were used for efficacy calculations. RESULTS: In Study 1, the control group had a geometric mean (GM) of 28.8 adult nematodes and the single treatment group had a GM of 3.4 (efficacy 88.3%). In Study 2, the control group had a GM of 14.3, the prevention group had a GM of 0 (efficacy 100%), while the treatment group had a GM of 0.1 (efficacy 99.4%). In Study 3, the GM worm burden in the control group was 32.6 compared to 0 in all three prevention groups (efficacy 100% for all of those groups). CONCLUSIONS: The monthly administration of Advocate® reliably eliminated early larval stages and thereby prevented lung damage from and patent infections with A. abstrusus in cats. Regarding treatment, a single application of Advocate® reduced the worm burden, but it did not sufficiently clear the infection. In contrast, three monthly treatments were safe and highly efficacious against A. abstrusus.
Asunto(s)
Enfermedades de los Gatos/tratamiento farmacológico , Enfermedades de los Gatos/prevención & control , Macrólidos/administración & dosificación , Metastrongyloidea/efectos de los fármacos , Neonicotinoides/administración & dosificación , Nitrocompuestos/administración & dosificación , Infecciones por Strongylida/veterinaria , Administración Tópica , Animales , Enfermedades de los Gatos/parasitología , Gatos , Esquema de Medicación , Composición de Medicamentos , Femenino , Larva/efectos de los fármacos , Estadios del Ciclo de Vida/efectos de los fármacos , Pulmón/efectos de los fármacos , Pulmón/parasitología , Masculino , Infecciones por Strongylida/tratamiento farmacológico , Infecciones por Strongylida/prevención & control , Resultado del TratamientoRESUMEN
BACKGROUND: The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic. METHODS: The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing 1.2-5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by their owners and general health conditions were recorded during the entire period of the study. RESULTS: The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete elimination (parasitological cure) of adult eye worms at Day 14 and Day 28 . The effectiveness of the treatment in the G1 group was 93.3 and 100% at Day 14 and Day 28 , respectively, when compared to group G2. Total worm count reduction from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic nature of the disease. CONCLUSIONS: Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective in the treatment of natural T. callipaeda infection in cats.
Asunto(s)
Enfermedades de los Gatos/parasitología , Oftalmopatías/veterinaria , Macrólidos/uso terapéutico , Neonicotinoides/uso terapéutico , Nitrocompuestos/uso terapéutico , Infecciones por Spirurida/veterinaria , Thelazioidea , Administración Tópica , Animales , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Combinación de Medicamentos , Oftalmopatías/tratamiento farmacológico , Oftalmopatías/parasitología , Macrólidos/administración & dosificación , Neonicotinoides/administración & dosificación , Nitrocompuestos/administración & dosificación , Infecciones por Spirurida/tratamiento farmacológicoRESUMEN
Thelazia callipaeda (Spirurida, Thelaziidae) has been documented as agent of ocular infection in domestic animals (dogs and cats), wildlife (e.g., foxes, hares, rabbits), and humans. In the last two decades, this parasitosis has been increasingly reported in several European countries. Both adult and larval stages of the eyeworm are responsible for symptoms ranging from mild (e.g., lacrimation, ocular discharge, epiphora) to severe (e.g., conjunctivitis, keratitis, and corneal opacity or ulcers). The present study evaluated the clinical efficacy and safety of imidacloprid 10% and moxidectin 2.5% spot on (Advocate(®), Bayer Animal Health) in comparison to milbemycin oxime/praziquantel tablets (Milbemax(®), Novartis-Animal Health), as positive control, in the treatment of canine thelaziosis in naturally infected dogs and, a third group was used as an untreated control. Forty-seven dogs (27 females and 20 males) harbouring at least one live adult worm of T. callipaeda in one eye were enrolled from an endemic area of southern Italy. Each dog was then weighed and assigned in accordance with a random treatment allocation plan to one of the treatment groups (G1: imidacloprid 10% and moxidectin 2.5% spot on, G2: Untreated control and G3: milbemycin oxime/praziquantel tablets). On Day (D) 7, 14, 28 and 35 dogs were physically examined and the infection level was assessed by examination of both eyes, including conjunctival pouch and third eyelid for live adult T. callipaeda count and clinical scores. Dogs in G1 were treated on D0 and D28, whereas those in G3 on D0 and D7. Efficacy in G1 was 100% at each day post treatment (p<0.01). For the G3 group efficacy was 57.39% on D7 (p<0.05), 92.79% on D14 and 100% on D28 and D35 (p<0.01). The application of the spot on formulation moxidectin 2.5% and imidacloprid 10% was highly effective in the treatment of canine thelaziosis caused by T. callipaeda. Advocate(®) spot on can be recommended for the control of T. callipaeda infection, considering that this formulation is currently licensed in Europe for the treatment of a wide range of parasites affecting dogs.